<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04635800</url>
  </required_header>
  <id_info>
    <org_study_id>CMHU650A12101</org_study_id>
    <nct_id>NCT04635800</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of IVT MHU650 in Macular Edema Patients</brief_title>
  <official_title>A First-in-human, Open-label, Single Ascending Dose Study to Assess Safety and Tolerability of Intravitreal MHU650 in Patients With Macular Edema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This open-label study is being conducted to evaluate the initial safety and tolerability of&#xD;
      IVT MHU650 in patients with DME, AMD, or RVO. The primary objective of this study is to&#xD;
      evaluate the safety and tolerability of single ascending doses of IVT MHU650 in patients with&#xD;
      macular edema. The secondary objective of this study is to evaluate the serum pharmacokinetic&#xD;
      profile of total MHU650 following single IVT dose of MHU650 in macular edema patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, multi-center, FIH study which employs a single ascending dose (SAD)&#xD;
      design to assess the safety, tolerability and pharmacokinetics (PK) of single IVT doses of&#xD;
      MHU650 in up to 24 patients with macular edema. The screening period for this study will be&#xD;
      up to 60 days. A single dose of MHU650 intravitreal injection will be administered at&#xD;
      Baseline / Day 1 in the study eye. The follow up period will last until Day 60 / end of study&#xD;
      (EOS) during which ophthalmic, medical and safety laboratories will be performed. A post&#xD;
      study safety phone contact call will occur 30 days after the EOS visit. Patients can receive&#xD;
      rescue treatment at any time during the study following MHU650 administration.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 10, 2020</start_date>
  <completion_date type="Anticipated">March 25, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 24, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>The primary objective of this open-label study is to evaluate the initial safety, tolerability, and pharmacokinetics (PK) of single IVT doses of MHU650 in up to 24 patients. The screening period will be up to 60 days. A single dose of MHU650 will be administered at Baseline / Day 1 in the study eye. The follow up period will last until Day 60 / end of study (EOS). A post study safety phone contact call will occur 30 days after the EOS visit. A total of up to 4 cohorts may be enrolled, with an additional optional lower or intermediate cohort of 6 participants.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open-label; no masking</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with ocular and nonocular adverse events</measure>
    <time_frame>Day 1 through Day 60</time_frame>
    <description>To evaluate the safety and tolerability of a single IVT dose of MHU650 over 2 months post dose by reviewing ophthalmic, medical examination and safety laboratories. To characterize ocular and non-ocular safety by the incidence of treatment-emergent adverse events (AEs) (new or worsening from baseline) summarized categorically by system organ class and/or preferred term.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of single dose of MHU650 - Cmax</measure>
    <time_frame>Days 1, 2, 5, 15, 29, 43 and 60</time_frame>
    <description>Assess serum PK profile of MHU650 by Cmax (if feasibile)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of single dose of MHU650 - Tmax</measure>
    <time_frame>Days 1, 2, 5, 15, 29, 43 and 60</time_frame>
    <description>Assess serum PK profile of MHU650 by Tmax (if feasibile)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of single dose of MHU650 - T1/2</measure>
    <time_frame>Days 1, 2, 5, 15, 29, 43 and 60</time_frame>
    <description>Assess serum PK profile of MHU650 by T1/2 (if feasibile)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of single dose of MHU650 - AUClast</measure>
    <time_frame>Days 1, 2, 5, 15, 29, 43 and 60</time_frame>
    <description>Assess serum PK profile of MHU650 by AUClast (if feasibile)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of single dose of MHU650 - AUCinf</measure>
    <time_frame>Days 1, 2, 5, 15, 29, 43 and 60</time_frame>
    <description>Assess serum PK profile of MHU650 by AUCinf (if feasibile)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Macular Edema</condition>
  <condition>Diabetic Macular Edema</condition>
  <condition>Neovascular Age-related Macular Degeneration</condition>
  <condition>Retinal Vein Occlusion</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 1; open-label, non-randomized, single administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 2; open-label, non-randomized, single administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 3, open-label; non-randomized, single administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 4, open-label, non-randomized, single administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MHU650</intervention_name>
    <description>MHU650 powder for solution for injection</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Patients with macular edema in at least one eye, including those with focal or diffuse&#xD;
             diabetic macular edema (DME), neovascular age-related macular degeneration (AMD), or&#xD;
             retinal vein occlusion (RVO), in the opinion of the investigator:&#xD;
&#xD;
          -  Early Treatment Diabetic Retinopathy (ETDRS) letter score in the study eye must be&#xD;
             worse than 60 letters (20/63) but better than 24 letters (20/320) at screening and&#xD;
             baseline. The ETDRS score in the non-study eye should be ≥ 60 letters at screening and&#xD;
             baseline.&#xD;
&#xD;
          -  Sufficiently clear ocular media and adequate pupil dilation to permit fundus&#xD;
             photographs of adequate clarity to measure diameters of retinal arteries and veins&#xD;
&#xD;
          -  Vital signs as specified in the protocol&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
        - Proliferative diabetic retinopathy in the study eye&#xD;
&#xD;
        The following is permitted as an exception:&#xD;
&#xD;
          -  Tufts of neovascularization less than one disc area with no vitreous hemorrhage&#xD;
&#xD;
          -  Focal, peripheral retinal areas treated with photocoagulation with fewer than 30 laser&#xD;
             burns performed at least 6 months preceding Day 1&#xD;
&#xD;
               -  Patients with type 1or type 2 diabetes who have hemoglobin A1C of ≥ 12 at&#xD;
                  screening&#xD;
&#xD;
               -  Other ocular conditions as specified in the protocol&#xD;
&#xD;
               -  Systemic conditions as specified in the protocol&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Huntington Beach</city>
        <state>California</state>
        <zip>92647</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92697</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rancho Cordova</city>
        <state>California</state>
        <zip>95670</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Altamonte Springs</city>
        <state>Florida</state>
        <zip>32701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Deerfield Beach</city>
        <state>Florida</state>
        <zip>33064</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96813</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hagerstown</city>
        <state>Maryland</state>
        <zip>21740</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78793</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Arecibo</city>
        <zip>00612</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 13, 2020</study_first_submitted>
  <study_first_submitted_qc>November 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 19, 2020</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Macular degeneration</keyword>
  <keyword>age-related macular degeneration</keyword>
  <keyword>dry macular degeneration</keyword>
  <keyword>wet macular degeneration</keyword>
  <keyword>Diabetic Macular Edema</keyword>
  <keyword>DME</keyword>
  <keyword>Neovascular age-related macular edema</keyword>
  <keyword>nAMD</keyword>
  <keyword>Retinal Vein Occlusion</keyword>
  <keyword>RVO</keyword>
  <keyword>MHU650</keyword>
  <keyword>macular edema</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Retinal Vein Occlusion</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

